Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Novartis”

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With SchizophreniaRecruiting
NCT07467993Phase 2Updated Jul 29, 2026
Sponsor: Novartis Pharmaceuticals
Schizophrenia
United States, Bulgaria
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisRecruiting
NCT07225504Phase 3Updated Jul 29, 2026
Sponsor: Novartis Pharmaceuticals
Secondary Progressive Multiple Sclerosis (SPMS)
United States, Argentina, Australia, Austria, Belgium +27 more
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)Completed
NCT05996835Phase 2Updated Jul 29, 2026
Sponsor: Novartis Pharmaceuticals
Acute Kidney Injury Due to Sepsis
United States, Argentina, Australia, Austria, Belgium +12 more
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgANRecruiting
NCT06797518Phase 2Updated Jul 29, 2026
Sponsor: Novartis Pharmaceuticals
Glomerulonephritis, IGA · Immunoglobulin A Nephropathy
United States, Argentina, Israel, Malaysia, Saudi Arabia
A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast CancerCompleted
NCT06075758N/AUpdated Jul 29, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
Jordan, Oman, United Arab Emirates
Pan Tumor Rollover StudyRecruiting
NCT03899155Phase 2Updated Jul 29, 2026
Sponsor: Bristol-Myers Squibb
Cancer
United States, Argentina, Australia, Austria, Belgium +33 more
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia GravisRecruiting
NCT06744920Phase 3Updated Jul 29, 2026
Sponsor: Novartis Pharmaceuticals
Generalized Myasthenia Gravis
United States, Argentina, Australia, Belgium, Brazil +15 more
Pelacarsen Roll-over Extension ProgramRecruiting
NCT06875973Phase 3Updated Jul 29, 2026
Sponsor: Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
United States, Puerto Rico
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.Active Not Recruiting
NCT05739383Phase 3Updated Jul 29, 2026
Sponsor: Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
United States, Argentina, Australia, Austria, Belgium +37 more
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear PalsyRecruiting
NCT07498426Phase 3Updated Jul 29, 2026
Sponsor: Novartis Pharmaceuticals
Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
United States, Australia, China, France, Germany +5 more
VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart DiseaseActive Not Recruiting
NCT06249165Phase 4Updated Jul 29, 2026
Sponsor: Duke University
Atherosclerotic Cardiovascular Disease
United States
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant MelanomasActive Not Recruiting
NCT05415072Phase 1, Phase 2Updated Jul 28, 2026
Sponsor: Novartis Pharmaceuticals
Metastatic Uveal Melanoma
United States, Australia, France, Germany, Netherlands +2 more
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid TumorsRecruiting
NCT07630961Phase 1Updated Jul 28, 2026
Sponsor: Novartis Pharmaceuticals
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) · Non-small Cell Lung Cancer (NSCLC) · HR+/HER2- Ductal Breast Cancer (BC) · HR+/HER2- Lobular Breast Cancer (BC)
Japan
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid TumorsRecruiting
NCT07660055Phase 1Updated Jul 28, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer · Non-small Cell Lung Cancer (NSCLC) · Gastric/Gastroesophageal Junction (GEJ) Cancer · Bladder Cancer
United States, Australia, Canada, Japan
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study TreatmentsActive Not Recruiting
NCT04058756Phase 1Updated Jul 28, 2026
Sponsor: Novartis Pharmaceuticals
Advanced Solid Tumors
United States, Belgium, Canada, China, Czechia +12 more
Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial InfarctionActive Not Recruiting
NCT06372925Phase 4Updated Jul 28, 2026
Sponsor: Novartis Pharmaceuticals
Plaque, Atherosclerotic
China
Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)Active Not Recruiting
NCT06155500Phase 1Updated Jul 28, 2026
Sponsor: Novartis Pharmaceuticals
Sickle Cell Disease
United States
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid TumorsRecruiting
NCT07006727Phase 1Updated Jul 28, 2026
Sponsor: Novartis Pharmaceuticals
Small Cell Lung Carcinoma · Large Cell Neuroendocrine Carcinoma of the Lung · Neuroendocrine Prostate Cancer · Gastroenteropancreatic Neuroendocrine Carcinoma
United States, Canada, South Korea
Study of PIT565 in Relapsed and/or Refractory B-cell MalignanciesActive Not Recruiting
NCT05397496Phase 1Updated Jul 28, 2026
Sponsor: Novartis Pharmaceuticals
B-cell Non-Hodgkin Lymphoma (B-NHL) · B-cell Acute Lymphoblastic Leukemia (B-ALL)
United States, Belgium, China, France, Israel +4 more
Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine ACompleted
NCT02328963Phase 4Updated Jul 27, 2026
Sponsor: University Hospital, Bordeaux
Transplantation Infection · Cytomegalovirus Infection
France
Phase II Study of BKM120 for Subjects With Recurrent GlioblastomaCompleted
NCT01339052Phase 2Updated Jul 27, 2026
Sponsor: L. Nicolas Gonzalez Castro, MD, PhD
Glioblastoma
United States
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial HypercholesterolemiaRecruiting
NCT06597006Phase 3Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Familial Hypercholesterolemia - Homozygous
United States, Austria, China, Germany, Greece +6 more
A Study of 177Lu-FAP-2286 in Advanced Solid TumorsRecruiting
NCT04939610Phase 1, Phase 2Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Solid Tumor
United States, Australia, Canada, France, Italy +1 more
A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With EltrombopagRecruiting
NCT07587723N/AUpdated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Immune Thrombocytopenia
Switzerland
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.Active Not Recruiting
NCT05201066Phase 2Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Myelodysplastic Syndromes · Leukemia, Myelomonocytic, Chronic
United States, Australia, Brazil, Canada, China +10 more

Previous page Next page